Abstract:Purpose: To determine the clinical and laboratory characteristics and outcomes of patients with chronic myelogenous leukemia (CML) in the lymphoid blastic phase. Patients and methods: Data from 296 patients with CML blastic-phase disease who were referred to our institution between 1967 and 1991 were analyzed. Sixty-eight patients had CML lymphoid blastic-phase disease. Pretreatment characteristics, responses to different therapies, and survival rates were evaluated. Results: Compared with patients having myeloid or undifferentiated blastic-phase disease, those with lymphoid morphology were significantly younger, presented with significantly lesser degrees of anemia, lower white blood cell and peripheral blast counts, higher percentages of marrow blasts, lower lactic dehydrogenase levels, and higher albumin levels. Accelerated-phase CML preceded the blastic phase in 40% of patients with lymphoid disease, compared with 54% of those with other morphologic findings (p = 0.03). The common acute lymphocytic leukemia antigen (CALLA) was expressed on lymphoid blasts in 97% of patients. The incidence of chromosomal abnormalities was similar in the three morphologic categories, although patients with lymphoid disease tended to have a lower incidence of trisomy 8 (17% versus 27%; p = 0.10) and of isochromosome 17 abnormalities (10% versus 17%; p not significant). The incidence of lymphoid blastic phase disease has not increased over the past decade, and it is not higher in patients with the chronic phase of the disease treated with alpha interferon. Patients with lymphoid disease had a significantly higher response rate to chemotherapy during the first salvage (49% versus below 20% for other morphologies; p < 0.001), particularly with vincristine, Adriamycin, and dexamethasone therapy (complete response rate of 61%). Survival during the blastic phase of the disease was also significantly longer in patients with lymphoid morphology than in those with other morphologies (median survival of 9 months versus 3 months; p = 0.01). The benefit associated with lymphoid blastic-phase morphology is brief, and plans for allogeneic bone marrow transplantation or experimental maintenance or consolidation programs should be implemented rapidly. Conclusions: Patients with CML lymphoid blastic-phase disease have different clinical and laboratory features than patients with other blastic-phase morphologies. In patients developing CML blastic-phase disease, distinguishing those with lymphoid transformation is extremely important because of the different therapeutic requirements (acute lymphocytic leukemia-type therapy) and prognostic implications.

Blast Phase of Chronic Myeloid Leukemia Presenting As Early T‐cell Precursor Lymphoblastic Leukemia

Blast phase of chronic myeloid leukemia presenting as early T-cell precursor acute lymphoblastic leukemia

Extramedullary blast crisis of CD 34 + CD 38-leukemia stem cells in chronic myeloid leukemia resistant to tyrosine kinase inhibitors : a report of two cases

T-Lymphoblastic Leukemia with T(9;22): Blast Phase of Chronic Myelogenous Leukemia or BCR-ABL- Positive T-Acute Lymphoblastic Leukemia?

Sudden Extramedullary Blast Crisis of Chronic Myeloid Leukemia Manifesting As T-cell Lymphoblastic Lymphoma.

Early T-cell Precursor Leukemia: a Subtype of High Risk Childhood Acute Lymphoblastic Leukemia

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

Prognostic Factors and Clinical Outcomes in Patients with Blast Phase Chronic Myeloid Leukemia

Bilineal Extramedullary Blast Crisis As an Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Literature Review

Chronic Myeloid Leukemia Unveils Its Dark Side: A Rare Case of Megakaryocytic Blast Crisis

Chronic Myeloid Leukemia Presenting in Lymphoblastic Crisis, a Differential Diagnosis with Philadelphia-positive B-lymphoblastic Leukemia.

An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease

t(15;17)(q24.1;q21.2)/ PML-RARA in blast phase of chronic myelogenous leukemia: a rare form of clonal evolution

T lymphoblastic lymphoma/acute lymphoblastic leukemia from blast crisis of chronic myelogenous leukemia—A case report and the review of literature

Clonal Evolution of AML1-ETO Coexisting with BCR-ABL and Additional Chromosome Abnormalities in a Blastic Transformation of Chronic Myeloid Leukemia

Extramedullary T‐lymphoblastic blast crisis in a young male with chronic myeloid leukemia: A rare presentation diagnosed on cytology and flow cytometric immunophenotyping

Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan

Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia

Blast Transformation of Chronic Myeloid Leukemia Driven by Acquisition of t(8;21)(q22;q22)/RUNX1::RUNX1T1: Selecting Optimal Treatment Based on Clinical and Molecular Findings